Sublocade is a new injectable form of buprenorphine (Suboxone) approved in 2017 by the FDA and now available.

 

Indication

Sublocade is indicated for adults with moderate to severe opioid use disorder who have been on a stable transmucosal dose of buprenorphine for at least 7 days (Suboxone, Subutex, Zubsolv, Bunavail).  This new treatment may be helpful for many patients with addiction to heroin, fentanyl, hydrocodone, oxycodone, morphine, and other opioids.

 

Medication facts

Sublocade is injected under the skin in the abdominal region and released slowly over the month.  It comes in 2 doses, 100mg and 300mg, in pre-filled syringes to be given by a health-care provider.

 

Cost

Costs will include clinical evaluation and treatment in addition to medication.  The cost of this new medication will be higher than Suboxone, but the exact cost to the patient including discounts and insurance coverage will vary.

 

References

https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm587312.htm

http://indivior.com/wp-content/uploads/2017/11/SUBLOCADE-Fact-Sheet.pdf

https://www.medscape.com/viewarticle/889462